Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Eiger BioPharmaceuticals, Inc. (EIGR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update"
03/16/2023 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
11/04/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Recent Highlights and Upcoming Milestones"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2019 EIGER BIOPHARMACEUTICALS, INC. Delaware 001-36183 33-0971591 Eiger BioPharmaceuticals, Inc. 2155 Park Blvd. Palo Alto, California 94306 272-6138 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement com...",
"Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update"
08/08/2019 8-K/A Quarterly results
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2019 EIGER BIOPHARMACEUTICALS, INC. Delaware 001-36183 33-0971591 Eiger Biopharmaceuticals, Inc. 2155 Park Blvd. Palo Alto, California 94306 272-6138 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communic...",
"Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update"
11/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 9, 2018 EIGER BIOPHARMACEUTICALS, INC. Delaware 001-36183 33-0971591 Eiger Biopharmaceuticals, Inc. 2155 Park Blvd. Palo Alto, California 94306 272-6138 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement com...",
"Eiger Bio Reports Third Quarter 2018 Financial Results • HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 • Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif., November 9, 2018"
08/13/2018 8-K Quarterly results
Docs: "Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results PALO ALTO, Calif., August 10, 2018"
05/11/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected...",
"Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results"
05/12/2017 8-K Form 8-K - Current report
05/18/2016 8-K Form 8-K - Current report
08/11/2015 8-K Quarterly results
Docs: "Celladon Reports Second Quarter 2015 Financial Results"
05/14/2015 8-K Quarterly results
Docs: "Celladon Reports First Quarter 2015 Financial Results"
11/12/2014 8-K Quarterly results
Docs: "Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights"
08/08/2014 8-K Quarterly results
Docs: "Celladon Reports Second Quarter 2014 Financial Results and Recent Highlights - Conference Call Today at 8:30 a.m. Eastern Time -",
"Excerpt of transcript from conference call held on August 7, 2014"
05/13/2014 8-K Quarterly results
Docs: "Celladon Reports First Quarter 2014 Financial Results and Recent Highlights — Conference Call Today at 4:30 p.m. Eastern Time"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy